NASDAQ, ALKS - Alkermes Plc
The following business section contains forward-looking statements which
involve risks and uncertainties. Our actual results could differ materially from
those anticipated in these forward-looking statements as a result of certain
factors. See ?Risk Factors? and ?Management?s Discussion and Analysis of
Financial Condition and Results of Operations ? Forward-Looking Statements.?
General
Alkermes, Inc. (together with its subsidiaries, referred to as ?we?, ?us?,
?our? or the ?Registrant?), a Pennsylvania corporation organized in 1987, is a
biotechnology company that develops products based on sophisticated drug
delivery technologies to enhance therapeutic outcomes in major diseases. We have
two commercial products. RISPERDAL? CONSTA?[(risperidone) long-acting injection]
is the first and only long-acting atypical antipsychotic medication approved for
use in schizophrenia and is marketed worldwide by Janssen-Cilag (?Janssen?), a
subsidiary of Johnson & Johnson. ...
Read SEC Filing on NASDAQ.com »